Neoadjuvant therapy (NAT) is currently administered to patients with locally advanced breast cancers, to breast cancer of poor prognosis (triple-negative and HER2-positive tumors, or with nodal involvement and/or high proliferation rates), or to early-stage breast cancer having an indication of systemic therapy (1–4). This evidence concerns the gene ERBB2 and breast carcinoma.